The Oncology Partnering Forum provides a unique opportunity for tech transfer professionals from industry and academia to network and explore opportunities to collaborate in this tech sector.
Lisa Mueller
Casmir Jones
Host of Podcast AUTM on the Air
View Lisa's Bio

Presentation: Cancer Grand Challenge

Noon – 12:20 p.m. ET

Cancer Grand Challenge 2021 is a joint effort between NCI and Cancer Research UK to fund four teams tackling focus areas identified as advancing bold cancer research and improving patient outcomes.

Learn about this trans-Atlantic collaborative funding opportunity and its unique intellectual property ownership and licensing structures.

Alessia Errico Alessia Errico
Assoc. Director Search & Evaluation and Entrepreneurial Program Lead
Cancer Research UK
Andrew Kurtz Andrew Kurtz
Program Director
National Cancer Institute
What You’ll Learn
  • Current status of 2021 Challenge and upcoming 2023 Challenge
  • Rules for teams comprising industry and academic members
  • Role of Cancer Research Horizons in managing and commercializing Challenge inventions
  • Resources and opportunities offered to early-stage researchers

Panel Discussion: Partnering in the Crowded Immuno-Oncology Landscape

12:20 – 1 p.m. ET

Immuno-Oncology (I-O) encompasses a wide array of pharmaceutical and biologics targeting various pathways in a patient's own immune system to treat a wide array of cancers. Several I-O agents recently obtained product approvals indicating strong investment appetite to develop even more I-O agents. But how do investors differentiate new I-O assets from the pack?

Hear from panelists in venture capital and industry about the current I-O landscape and opportunities for co-development or licensing with academic investigators.

Neil Bajpayee Neil Bajpayee
Associate Director of Alliance Management
Kite Pharma
View Neil's Bio
Ruben FloresRussell DeKelver
Associate Director of Search & Evaluation
Merck & Co
Ruben FloresRubén Flores-Saaib
Innovations and Partnership Lead
General Inception
Natalia Greco Natalie Greco
Director of Intellectual Property and Licensing
Parker Institute for Cancer Immunotherapy
Natalia Greco Rajul Jain
Managing Director
Vida Ventures

Company Presentations: Pipeline and Priorities in Oncology Discovery

1 – 2 p.m. ET

Tech transfer offices are constantly asked to describe how their academic technology aligns with the development goals of potential company partners.

Hear from these leading oncology companies as they share valuable intel on their discovery pipeline, current scouting priorities for collaboration and licensing with academic partners, and their preferred format, content and process for vetting academic technologies.

Company Presenters
Stacey HeroStacey Hero
VP Business Development/Chief of Staff
Drew HertigDrew Hertig
Senior Director Corporate Development
Qualigen Therapeutics
Natalia UlyanovaNatalia Ulyanova
Director Oncology Business Development
Astellas Pharma
Jenny WangJenny Wang
Director Search & Evaluation Oncology
Hong XinHong Xin
Senior Director External Innovation Search & Evaluation
Johnson & Johnson Innovations

Break-out Sessions: Meet the Presenters

2 p.m. ET

Stay for the networking. Dedicated break-out rooms will be provided for all presenters and panelists. It's your opportunity to ask questions, engage in conversation and make connections with the presenters.

Thank You to Our Sponsor